SCHEMBL17482014

SCHEMBL17482014

Cc1ccc2c(c1)c1cc(C(C)(C)C)ccc1n2CCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.61
▸ POLB P06746 1/20 0.61
▸ HSD17B10 Q99714 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ FABP3 P05413 1/20 0.49
▸ FABP4 P15090 1/20 0.49
▸ FABP5 Q01469 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.46
▸ DNMT1 P26358 3/20 0.45
▸ PTGES2 Q9H7Z7 1/20 0.45
▸ RORA P35398 2/20 0.44
▸ RORC P51449 2/20 0.44
▸ RORB Q92753 2/20 0.44
▸ TBXAS1 P24557 1/20 0.44
▸ CCR9 P51686 1/20 0.43
▸ PGR P06401 1/20 0.43
▸ KMO O15229 1/20 0.43
▸ PTGDR2 Q9Y5Y4 3/20 0.42
▸ AKR1B1 P15121 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16156848 0.90 KDM4E (0.73) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL16156846 0.86 FABP4 (0.69) KDM4EFABP3FABP4FABP5ALDH1A1
SCHEMBL17482066 0.83 FABP4 (0.73) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL16156845 0.82 KDM4E (0.63) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL16156844 0.82 KDM4E (0.63) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL17482011 0.82 KDM4E (0.63) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL31305276 0.78 FABP4 (0.60) KDM4EPOLBHSD17B10L3MBTL1FABP3
SCHEMBL13026402 0.77 RORC (0.47) KDM4EHSD17B10ALDH1A1DNMT1PTGES2
SCHEMBL2604388 0.75 TSHR (0.46) KDM4EPOLBHSD17B10ALDH1A1RORA
SCHEMBL24797020 0.75 RORA (0.40) KDM4EPOLBHSD17B10L3MBTL1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862684-B2 Modulation of K2P channels THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-01-09 — — US disclosed
US-20160031814-A1 MODULATION OF K2P CHANNELS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-04 — — US disclosed
US-20160031814-A1 MODULATION OF K2P CHANNELS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031814-A1 MODULATION OF K2P CHANNELS KCNJ2, KCNK2, KCNN3 KDM4E 1102/4885POLB 3655/4885HSD17B10 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback